Translating Ribosome Affinity Purification (TRAP) for RNA Isolation from Endothelial Cells In Vivo
May 25th, 2019
11.4K views
We present an approach to purify ribosome-bound mRNA from vascular endothelial cells (ECs) directly in mouse brain, lung and heart tissues via EC-specific genetic tag of enhanced green fluorescence protein (EGFP)in ribosomes in combination with RNA purification.
Overview
This study presents a novel approach to purify ribosome-bound mRNA from vascular endothelial cells (ECs) in mouse brain, lung, and heart tissues. By utilizing an EC-specific genetic tag of enhanced green fluorescence protein (EGFP) in ribosomes, researchers can effectively isolate mRNA for further analysis.
Key Study Components
Area of Science
- Endothelial cell biology
- Angiogenesis
- Transcription regulation
Background
- Endothelial cells play a crucial role in vascular biology.
- Understanding mRNA dynamics in ECs can reveal insights into cardiovascular diseases.
- Transgenic mouse models allow for targeted studies of gene function.
- Enhanced GFP tagging provides a method for isolating specific mRNA populations.
Purpose of Study
- To develop a method for purifying ribosome-bound mRNA from ECs.
- To facilitate downstream analysis of transcripts in various tissues.
- To enhance understanding of transcriptional mechanisms in angiogenesis.
Methods Used
- Creation of transgenic mouse lines with EGFP-tagged ribosomes.
- Isolation of ribosome-bound mRNA from endothelial cells.
- Analysis of purified mRNA for transcriptomic studies.
- Application of genetic engineering techniques to study gene function.
Main Results
- Successful purification of mRNA from ECs in multiple tissues.
- Demonstration of the effectiveness of EGFP tagging in mRNA isolation.
- Insights into the transcriptional regulation of angiogenesis.
- Potential applications in understanding cardiovascular diseases.
Conclusions
- The method provides a valuable tool for studying endothelial cell function.
- Purified mRNA can lead to new discoveries in vascular biology.
- This approach may enhance research on diseases involving angiogenesis.
Frequently Asked Questions
What is the significance of purifying ribosome-bound mRNA?
Purifying ribosome-bound mRNA allows researchers to study the specific transcripts being translated in endothelial cells, providing insights into their functional roles.
How does the EGFP tagging work?
EGFP tagging involves genetically modifying endothelial cells to express enhanced green fluorescence protein, which labels ribosomes and facilitates mRNA isolation.
What tissues were studied in this research?
The study focused on mouse brain, lung, and heart tissues to analyze endothelial cell mRNA.
What are the potential applications of this research?
This research can lead to advancements in understanding cardiovascular diseases and the mechanisms of angiogenesis.
Who conducted this research?
The research was conducted by Bin Ren and his laboratory at the University of Alabama at Birmingham School of Medicine.
What is the main focus of Bin Ren's laboratory?
The laboratory focuses on endothelial cell biology, angiogenesis, and transcription regulation in the context of cardiovascular diseases and cancers.
Executive Industry Relevance
Translating Ribosome Affinity Purification (TRAP) enables direct in vivo isolation of ribosome-bound RNA from specific cell types, such as vascular endothelia, providing a physiologically relevant snapshot of translatome dynamics. This approach addresses a key discovery-stage challenge: obtaining cell-type-specific transcriptional data without the artifacts of in vitro culture or whole-tissue homogenization. By capturing actively translated mRNA in native tissue environments, TRAP supports mechanistic de-risking of angiogenic targets and improves predictive confidence in preclinical target validation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by isolating translatome from genetically defined endothelial cell populations in vivo.
- Operational Value: Provides a direct readout of gene expression regulation in angiogenesis pathways under physiological conditions.
- Predictive Value: Supports target confidence by linking ribosome-associated mRNA levels to functional angiogenic outputs such as ephrin B2 and DLL4 expression.
Screening & Assay Development
- Scientific Value: Generates high-fidelity RNA inputs for downstream qPCR and sequencing assays that reflect active translation in endothelia.
- Operational Value: Standardizes sample preparation through GFP-tagged ribosome immunoprecipitation, reducing variability from cellular heterogeneity.
- Scalability: Enables reproducible isolation across lung, heart, and brain endothelia when optimized for RNase-free conditions and antibody concentration.
Translational & Preclinical Research
- Translational Continuity: Bridges in vitro findings with in vivo validation by confirming angiogenic gene regulation in intact tissues.
- Mechanistic De-risking: Confirms that observed transcriptional changes in EC-specific models are reflected at the translational level.
- Disease Relevance: Applicable to cardiovascular disease and cancer models where endothelial transdifferentiation and angiogenesis are pathogenic drivers.
Pipeline & Workflow Integration
TRAP fits within the discovery continuum from target hypothesis testing to lead identification by providing mechanistic insight into angiogenic signaling pathways in native endothelial cells.
- Discovery Biology: Supports pathway clarification by isolating translatome from ECs with defined genetic perturbations, such as CD-36 deficiency.
- Screening: Produces standardized RNA yields suitable for quantitative assays when tissue processing includes cycloheximide to halt translation and RNase inhibitors to preserve integrity.
- Analytics: Enables quantification of ribosome-bound transcripts via spectrophotometry and qPCR, facilitating comparison across genotypes and treatment conditions.
- Translational Research: Connects genetic manipulation to functional outcomes by validating that changes in angiogenic gene expression are reflected in actively translated mRNA pools.
- Enterprise Reuse: Establishes a reusable platform for cell-type-specific translatome profiling across multiple organs and disease models.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by distinguishing transcriptional from translational regulation in angiogenic pathways.
- Operational Value: Enhances reproducibility through standardized buffer preparation, antibody-bead coupling, and RNase-free workflows.
- Strategic Value: Improves go/no-go decisions by providing translational-level evidence for target engagement in angiogenesis.
- Portfolio Impact: Enables risk-adjusted prioritization of targets based on concordant changes in translatome and phenotype.
Implementation Considerations
- Requires expertise in transgenic mouse handling, genotyping, and endothelial tissue dissection.
- Depends on access to motor-driven homogenizers, magnetic racks, and centrifuges capable of 4°C operation.
- Necessitates RNase-free zones, frequent glove changes, and decontaminated surfaces to prevent RNA degradation.
- Requires optimization of GFP antibody concentration and RNase inhibitor levels in lysis buffer for consistent yield across tissue types.
- Limited by low RNA yield in certain tissues (e.g., heart) and previously frozen samples, necessitating protocol optimization.
Biopharma FAQs
Why is genotyping essential before TRAP-based RNA isolation?
Genotyping confirms the presence of the GFP-tagged ribosome construct in endothelial cells, which is required for immunoprecipitation using anti-GFP beads. Without confirmation of transgene expression, particularly homozygosity, the affinity purification step will fail to isolate ribosome-bound RNA. This step ensures that downstream RNA yield and specificity are not compromised by lack of target.
How does cycloheximide treatment improve the accuracy of translatome profiling?
Cycloheximide halts translation elongation, freezing ribosomes on mRNA and preserving the in vivo translatome state at the moment of tissue harvest. This prevents post-euthanasia changes in ribosome-mRNA associations that could distort the snapshot of active translation. By stabilizing polysomes, it ensures that the isolated RNA reflects the translational profile prior to euthanasia.
What role do DHPC and CA-630 lipids play in the TRAP workflow?
DHPC and CA-630 lipids are added to the lysate to facilitate phase separation, helping to isolate protein complexes from other intracellular components during ribosome purification. This step reduces contamination from non-ribosomal proteins and nucleic acids, improving the specificity of the immunoprecipitation. Effective phase separation is critical for obtaining clean ribosome-bound RNA preparations.
Why is RNase-free workflow critical for TRAP RNA yield and quality?
RNase contamination leads to RNA degradation, which directly reduces yield and compromises the integrity of downstream applications like qPCR and sequencing. The protocol emphasizes RNase-free plastic ware, reagents, and frequent glove changes to maintain RNA stability. Establishing an RNase-free zone is especially important given the low baseline yields observed in heart and frozen tissues.
What instrumentation is required for effective homogenization in TRAP?
A motor-driven homogenizer is recommended to increase RNA yield by efficiently lysing tissue while preserving ribosome-mRNA complexes. However, frequency and duration must be optimized to avoid RNA degradation from excessive mechanical shear. Ideal settings are empirically determined per device to balance homogenization efficiency with RNA integrity.
